Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07141277 · ClinicalTrials.gov registry record
GRANITE: Airsupra Effectiveness in the Real World
A clinical trial of Asthma, sponsored by AstraZeneca.
- Recruiting
- Registry status
- 4,000
- Enrollment target
- 1
- Study location
NCT07141277: Recruiting study of Asthma, sponsored by AstraZeneca.
NCT07141277 is a study of Asthma that is actively recruiting participants, run by AstraZeneca. The registered enrollment target is 4,000 participants, above the 1,553-participant average among 374 other Asthma trials with a reported enrollment target (158% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07141277, a study of Asthma, is actively recruiting participants, sponsored by AstraZeneca.
- RECRUITING
- Registry status
- 4,000 participants
- Enrollment target
- 1
- Study location
Study Summary
The GRANITE study aims to evaluate the effectiveness of Airsupra versus albuterol in reducing asthma exacerbation risk in a real-world US population.
Primary Outcome
Patient characteristics including demographics, clinical characteristics, asthma treatments, dosing, adherence to maintenance, asthma exacerbations, HCRU, and asthma severity defined per GINA will be described during the 12-month baseline period using descriptive statistics.
Conditions Studied
Interventions
- OTHER None (Observational study)
Study Locations (1)
Delaware
- AstraZeneca - Wilmington
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4,000 participants |
| Start Date | 2025-07-09 |
| Est. Completion | 2026-06-30 |
What NCT07141277 shows while recruiting
NCT07141277 is an observational study that tracks outcomes without assigning an intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,553-participant average among 374 other Asthma trials with a reported enrollment target (158% higher).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 1 intervention - of which None (Observational study) is the first listed.
NCT07141277 reports a single indexed study location in Delaware.
Frequently Asked Questions
What is clinical trial NCT07141277 about?
NCT07141277 is a clinical study titled "GRANITE: Airsupra Effectiveness in the Real World". The GRANITE study aims to evaluate the effectiveness of Airsupra versus albuterol in reducing asthma exacerbation risk in a real-world US population.
What is the current status of trial NCT07141277?
This trial is currently recruiting. The enrollment target is 4,000 participants. The study started on 2025-07-09. Estimated completion is 2026-06-30.
What conditions does trial NCT07141277 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT07141277?
The interventions under investigation include: None (Observational study) (OTHER).
Who is sponsoring clinical trial NCT07141277?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07141277 being conducted?
This trial has 1 study location across Delaware. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT07141277's enrollment target sits among peer trials
4,000 12th of 374 higher than 363 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Innate Immunity in Allergic Asthma
RECRUITING
-
Automated Inhaler Monitoring for Asthma Medication Usage
RECRUITING · NA
-
Impact of Metabolic Dysfunction and Mucus Plugging on Asthma Physiology
RECRUITING
-
Depemokimab Asthma Imaging and Bronchoscopy Sub-Study
RECRUITING · Phase 3
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00227253 · 4,000 participants
Chromosome 18 Clinical Research Center
- NCT00811148 · 4,000 participants
Florida Center for Brain Tumor Research
- NCT00897117 · 4,000 participants
Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer
- NCT00899301 · 4,000 participants
Collecting and Storing Tissue Samples From Women With or Without Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI